Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, today provided an update on the continued advancement of its proprietary AI platform and robotics integration as it approaches initial commercial deployment. Following the successful integration of approximately 28 million scientific abstracts - representing the…